Skip to main content

Table 5 Univariate analysis of clinical characteristics on progression free and overall survival in patients with metastatic non-small cell lung cancer

From: Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Variable PFS: HR, (95% CI) P = value OS: HR, (95% CI) P = value (a)
Age < 60 1.31 (0.96-1.79) 0.08 1.42 (1.03-1.95) 0.03
Gender (Female/Male) 1.14 (0.82-1.58) 0.41 0.97 (0.7-1.35) 0.88
Race (AA/White) 0.89 (0.65-1.20) 0.44 1.08 (0.8-1.47) 0.59
Histology (Adeno/Other) 1.03 (0.76-1.4) 0.82 1.01 (0.74-1.38) 0.90
PS (0-1/ 2–4) 0.62 (0.43-0.89) 0.009 0.64 (0.44-0.93) 0.01
Mets (1-2/ >2) 0.47 ( 0.34-0.64) <0.0001 0.54 (0.39-0.73) 0.0001
No chemotherapy 2.25 (1.62-3.13) <0.0001 2.36 (1.7-3.2) <0.0001
ALC <1 1.61 (1.02-2.53) 0.03 1.82 (1.16-2.87) 0.009
NLR < 5 0.58 (0.42-0.8) 0.001 0.57 (0.41-0.79) 0.0008
ALI < 18 2.26 (1.65-3.09) <0.0001 1.97 (1.45-2.68) <0.0001
  1. a) Cox-proportional hazard regression model.
  2. Abbreviations: AA African Americans, Adeno Adenoacrinoma, ALC Absolute lymphocyte count, ALI Advanced lung cancer inflammation index, PS performance status, Mets metastatic sites, NLR Neutrophil/lymphocyte ratio. Significant results shown in bold.